d-ribose-l-cysteine 561 views0 applications

Australian Approved Name (AAN): d-ribose-l-cysteine

Common name/s and synonyms: 2-(1,2,3,4-Tetrahydroxybutyl)thiazolidine-4-carboxylic acid

Mandatory components: Cysteine

Warnings and restrictions: Only for use in oral medicines. The medicine must provide no more than 450mg of cysteine per maximum recommended daily dose.

Allowable purpose of the ingredient: Active

TGA reference: CHEMID plus (National Library of Medicine)

Apply for this resource
Share this resource

Advanced Wellness Regulatory Solutions are a team of highly skilled professionals who specialise in providing timely and reliable regulatory and research & development advice.



While we take all measures to ensure that the information provided on this site is accurate, before relying on the material in any important matter, users should carefully evaluate its accuracy, completeness and relevance for their purposes, and should obtain any appropriate professional advice relevant to their particular circumstances.


Want to stay up to date with the latest industry changes and updates? Signup to our newsletter below.